-

New Cation Trap Column Workflow Improves Uptime for Anionic Contaminants Testing of Industrial Waters

The Thermo Scientific Dionex CR-CTC III application workflow offers cost-efficient trace-level analysis

SUNNYVALE, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, now offers nuclear power plants a new continuously regenerated cation trap column (CR-CTC) application workflow for robust and efficient trace anion contaminant testing of industrial waters.

The new Thermo Scientific Dionex CR-CTC III application workflow offers a solution to reduce the high cost and complexity of anion analysis in lithium borated water, and boiler and cooling water, in nuclear power plants. The workflow comprises the Thermo Scientific Dionex ICS-6000 capillary HPIC System or Thermo Scientific Dionex Integrion HPIC System and the Thermo Scientific Dionex IonPac AS28-Fast-4µm column, and allows for the determination of sub-µg/L anionic contaminants, utilizing a new single-step injection method of cation matrix elimination.

“This latest CR-CTC workflow aims to help reduce plant maintenance costs by minimizing plant and equipment corrosion through comprehensive trace anion contaminant analysis of industrial waters,” said Dino Alfano, vice president and general manager, ion chromatography and sample preparation, Thermo Fisher Scientific. “The new workflow provides optimum performance for nuclear power application requirements, such as removing lithium in borated waters by employing 100% carboxylate resin, and avoiding labile sulfonate that can end up in the cooling water as a corrosive anion.”

The new workflow offers a user-friendly experience, reducing the time required for training, and a single-step injection method of cation matrix elimination to increase productivity. The lower cost of ownership and maximized operational uptime help meet the ongoing increased energy demand.

Learn more about the new Thermo Scientific CR-CTC III application workflow.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The new Thermo Scientific Dionex CR-CTC III application workflow offers a solution to reduce the high cost and complexity of anion analysis.
Release Versions

Contacts

Media:
Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom